Pharmacogenetics of the effects of colesevelam on colonic transit in irritable bowel syndrome with diarrhea.

ABSTRACT:

Background

Protein products of klothoβ (KLB) and fibroblast growth factor receptor 4 (FGFR4) impact fibroblast growth factor 19-mediated feedback inhibition of hepatic bile acid (BA) synthesis. Variants of KLB and FGFR4 influence colonic transit (CT) in diarrhea-predominant irritable bowel syndrome (IBS-D).

Aim

The purpose of this study was to test the hypothesis that colesevelam's slowing effects on CT in IBS-D patients is influenced by genetic variants in KLB and FGFR4.

Methods

We examined pharmacogenetic effects of KLB and FGFR4 coding variants (SNPs) on scintigraphic CT response to the BA sequestrant, colesevelam 1.875 g b.i.d. versus placebo (PLA) for 14 days in 24 female IBS-D patients.

Results

FGFR4 rs351855 and KLB rs497501 were associated with differen

SUBMITTER: Wong BS 

PROVIDER: S-EPMC3809827 | biostudies-literature | 2012 May

REPOSITORIES: biostudies-literature